Mark S. Butler

14.7k total citations · 6 hit papers
147 papers, 8.7k citations indexed

About

Mark S. Butler is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Mark S. Butler has authored 147 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 45 papers in Pharmacology and 40 papers in Organic Chemistry. Recurrent topics in Mark S. Butler's work include Microbial Natural Products and Biosynthesis (32 papers), Marine Sponges and Natural Products (25 papers) and Antibiotic Resistance in Bacteria (24 papers). Mark S. Butler is often cited by papers focused on Microbial Natural Products and Biosynthesis (32 papers), Marine Sponges and Natural Products (25 papers) and Antibiotic Resistance in Bacteria (24 papers). Mark S. Butler collaborates with scholars based in Australia, Singapore and United States. Mark S. Butler's co-authors include Matthew A. Cooper, Mark A. T. Blaskovich, Avril A. B. Robertson, Antony D. Buss, Robert J. Capon, David L. Paterson, Karl A. Hansford, Johnny X. Huang, Siew Bee Ng and Luke O'neill and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Brain.

In The Last Decade

Mark S. Butler

142 papers receiving 8.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Role of Natural Product Chemistry in Drug Discovery

2004 1.0k citations Mark S. Butler Journal of Natural Products profile →
Natural products to drugs: natural product-derived compounds in clinical trials

2008 801 citations Mark S. Butler Natural Product Reports profile →
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

2018 669 citations Richard D. Gordon, Eduardo A. Albornoz et al. profile →
Natural product and natural product derived drugs in clinical trials

2014 463 citations Mark S. Butler, Avril A. B. Robertson et al. Natural Product Reports profile →
Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.

2022 167 citations Mark S. Butler, Valeria Gigante et al. Oxford University Research Archive (ORA) (University of Oxford) profile →
Antibiotics in the clinical pipeline as of December 2022

2023 129 citations Mark S. Butler, Ian R. Henderson et al. The Journal of Antibiotics profile →

Peers

Countries citing papers authored by Mark S. Butler

Since Specialization

Citations

This map shows the geographic impact of Mark S. Butler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Butler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Butler more than expected).

Fields of papers citing papers by Mark S. Butler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Butler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Butler. The network helps show where Mark S. Butler may publish in the future.

Co-authorship network of co-authors of Mark S. Butler

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Butler. A scholar is included among the top collaborators of Mark S. Butler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Butler. Mark S. Butler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Natural product-derived compounds in clinical trials and drug approvals 2025 ·Natural Product Reports ·Mark S. Butler, Robert J. Capon, Mark A. T. Blaskovich, Ian R. Henderson	4
2	PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson’s disease models 2025 ·Brain ·Eduardo A. Albornoz, Karine Mardon, Rajiv Bhalla, Vinod Kumar, (unknown), Gary Cowin, (unknown), Mark S. Butler, Ruby Pelingon, Richard D. Gordon, Rebecca C. Coll, Kate Schroder, Reena Halai, Angus M. MacLeod, Kim L. Matthews, Avril A. B. Robertson, Matthew A. Cooper, Trent M. Woodruff	0
3	Natural product inspired antibiotics approved for human use – 1943 to 2025 2025 ·Natural Product Reports ·Mark S. Butler, Robert J. Capon	0
4	The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives 2025 ·Journal of Natural Products ·Mark S. Butler, James J. La Clair	0
5	Antibiotics in the clinical pipeline as of December 2022 breakdown → 2023 ·The Journal of Antibiotics ·Mark S. Butler, Ian R. Henderson, Robert J. Capon, Mark A. T. Blaskovich	129
6	Antibacterial and Antifungal Alkaloids from Asian Angiosperms: Distribution, Mechanisms of Action, Structure-Activity, and Clinical Potentials 2022 ·Antibiotics ·Mazdida Sulaiman, Khoshnur Jannat, Veeranoot Nissapatorn, Mohammed Rahmatullah, Alok Kumar Paul, Maria de Lourdes Pereira, Mogana Rajagopal, Monica Suleiman, Mark S. Butler, Mohammed Khaled Bin Break, Jean-Frédéric F. Weber, Polrat Wilairatana, Christophe Wiart	28
7	Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed. breakdown → 2022 ·Oxford University Research Archive (ORA) (University of Oxford) ·Mark S. Butler, Valeria Gigante, Hatim Sati, Sarah Paulin, (unknown), John Rex, Prabhavathi Fernandes, César A. Arias, Mical Paul, Guy Thwaites, Lloyd G. Czaplewski, Richard A. Alm, Christian Lienhardt, Melvin Spigelman, Lynn L. Silver, Norio Ohmagari, Roman S. Kozlov, Stephan Harbarth, Peter Beyer	167
8	An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria 2020 ·Nature Communications ·Alysha G. Elliott, Johnny X. Huang, Søren Neve, Johannes Zuegg, Ingrid A. Edwards, Amy K. Cain, Christine J. Boinett, Lars Barquist, Carina Vingsbo Lundberg, Jason A. Steen, Mark S. Butler, Mehdi Mobli, (unknown), Mark A. T. Blaskovich, Sergio Lociuro, Magnus Strandh, Matthew A. Cooper	142
9	Detection and quantification of Staphylococcus aureus heterogeneity to identify antibiotic-induced persistence 2019 ·Access Microbiology ·(unknown), Mark S. Butler, Andrea Ranzoni, Matthew A. Cooper	1
10	Structure-Function Studies of Polymyxin B Lipononapeptides 2019 ·Molecules ·Alejandra Gallardo‐Godoy, Karl A. Hansford, Craig Muldoon, Bernd Becker, Alysha G. Elliott, Johnny X. Huang, Ruby Pelingon, Mark S. Butler, Mark A. T. Blaskovich, Matthew A. Cooper	31
11	Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate 2018 ·Journal of Antimicrobial Chemotherapy ·Miranda E. Pitt, Minh Duc Cao, Mark S. Butler, Soumya Ramu, Devika Ganesamoorthy, Mark A. T. Blaskovich, Lachlan Coin, Matthew A. Cooper	14
12	Anti-infective activities of 11 plants species used in traditional medicine in Malaysia 2018 ·Experimental Parasitology ·(unknown), Md Shahadat Hossan, Veeranoot Nissapatorn, Chairat Uthaipibull, Parichat Prommana, Teng-Jin Khoo, Mohammed Rahmatullah, Tooba Mahboob, Chandramathi Samudi Raju, Hassan Mahmood Jindal, Banasri Hazra, Mohd Ridzuan Mohd Abd Razak, Vijay Kumar Prajapati, Rajan Kumar Pandey, Norhaniza Aminudin, Khozirah Shaari, Nor Hadiani Ismail, Mark S. Butler, Владимир В. Зарубаев, Christophe Wiart	12
13	Analysis of the clinical antibacterial and antituberculosis pipeline 2018 ·The Lancet Infectious Diseases ·Ursula Theuretzbacher, (unknown), Peter Beyer, Mark S. Butler, Lloyd G. Czaplewski, Christian Lienhardt, Lorenzo Moja, Mical Paul, Sarah Paulin, John Rex, Lynn L. Silver, Melvin Spigelman, Guy Thwaites, Jean‐Pierre Paccaud, Stéphan Harbarth	159
14	Evidence against a role for NLRP3-driven islet inflammation in db/db mice 2018 ·Molecular Metabolism ·Hélène L. Kammoun, Tamara L. Allen, Darren C. Henstridge, (unknown), Rebecca C. Coll, Graeme I. Lancaster, (unknown), Saskia Reibe, Jeng Yie Chan, Mohammed Bensellam, D. Ross Laybutt, Mark S. Butler, Avril A. B. Robertson, Luke O'neill, Matthew A. Cooper, Mark A. Febbraio	32
15	GMP Synthase Is Required for Virulence Factor Production and Infection by Cryptococcus neoformans 2017 ·Journal of Biological Chemistry ·Jessica L. Chitty, (unknown), Simon J. Williams, Yasuhiro Koh, Elizabeth C. Corfield, Mark S. Butler, Avril A. B. Robertson, Matthew A. Cooper, Ulrike Kappler, Boštjan Kobe, James A. Fraser	16
16	Antibiotics in the clinical pipeline at the end of 2015 2016 ·The Journal of Antibiotics ·Mark S. Butler, Mark A. T. Blaskovich, Matthew A. Cooper	273
17	Structure aided design of chimeric antibiotics 2012 ·Bioorganic & Medicinal Chemistry Letters ·Tomislav Karoli, Sreeman Mamidyala, Johannes Zuegg, Scott Fry, (unknown), Tanya A. Bradford, Praveen K. Madala, Johnny X. Huang, Soumya Ramu, Mark S. Butler, Matthew A. Cooper	33
18	Natural products to drugs: natural product-derived compounds in clinical trials breakdown → 2008 ·Natural Product Reports ·Mark S. Butler	801
19	Mother Nature’s gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery 2007 ·Birkhäuser Basel eBooks ·Mark S. Butler, David Newman	41
20	NMR spectral assignments of three aspidofractinine alkaloids, kopsine, fruticosine and fruticosamine 2005 ·Magnetic Resonance in Chemistry ·Robert P. Glover, Yoganathan Kanagasundaram, Mark S. Butler	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact